Shanghai Junshi Bioscience

• A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Phase 3, Recruiting, 282 people, 9 Sept 2026

• NCT07503756

  Phase 2, Recruiting, 80 people, 31 Mar 2026

• NCT07284134

  Phase 3, Recruiting, 560 people, 16 Dec 2025

• NCT07081022

  Phase 2, Active, not recruiting, 180 people, 23 Jul 2025

• NCT06944470

  Phase 2, Active, not recruiting, 78 people, 25 Apr 2025

• NCT06885385

  Phase 2, Recruiting, 60 people, 20 Mar 2025

• NCT06839105

  Phase 1, Recruiting, 214 people, 21 Feb 2025

• NCT06139211

  Phase 1/2, Completed, 66 people, 18 Nov 2023

• NCT05800340

  Collaborator, Phase 2, Recruiting, 30 people, 5 Apr 2023

• NCT05757492

  Collaborator, Phase 1, Terminated, 22 people, 7 Mar 2023

• NCT05664971

  Phase 1/2, Completed, 119 people, 27 Dec 2022

• NCT05502393

  Phase 1, Active, not recruiting, 133 people, 16 Aug 2022

• NCT05342194

  Phase 3, Recruiting, 480 people, 22 Apr 2022

• NCT05173246

  Collaborator, Phase 2, Recruiting, 43 people, 29 Dec 2021

• NCT04907370

  Collaborator, Phase 3, Active, not recruiting, 532 people, 28 May 2021

• NCT04890522

  Collaborator, Phase 2/3, Not yet recruiting, 622 people, 18 May 2021

• NCT04848753

  Phase 3, Active, not recruiting, 663 people, 19 Apr 2021

• NCT04723004

  Phase 3, Completed, 326 people, 25 Jan 2021

• NCT04568304

  Phase 3, Withdrawn, 0 people, 29 Sept 2020

• NCT04250948

  Collaborator, Phase 2, Status unknown, 108 people, 31 Jan 2020

Sources: clinicaltrials.gov